Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Big Billion Indian COVID 19 Vaccine Challenge

The Big Billion Indian COVID 19 Vaccine Challenge Indian Journal of Surgical Oncology (March 2021) 12(1):3–4 https://doi.org/10.1007/s13193-021-01280-1 EDITORIAL 1 2,3 Arvind Krishnamurthy & K. S. Gopinath Published online: 1 February 2021 Indian Association of Surgical Oncology 2021 The front runner vaccine candidates for India’s COVID-19 response seems to be the vaccines developed by Oxford- “My advice to anyone offered the vaccine is to take it. AstraZeneca and the Bharath Biotech thus far. Although If I can have it at 90, then you can have it too.” Pfizer India has formally approached the Drugs Controller Margaret Keenan (First person in the world to have General of India (DCGI) for EUA of its Covid-19 vaccine, th the Covid–19 vaccine on December 8 2020) there seems to be no clear roadmap for the availability of the mRNA vaccines developed by Pfizer as well as the Moderna Come 2021, COVID-19 vaccination is expected to be one in India till date. It must be noted that the specialized cold of the most eagerly awaited events in the timelines of every storage requirements for the above mRNA vaccines may be nation world-wide and India is no exception to this mammoth a deterrent to its large-scale use in India. This is a rapidly global http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png "Indian Journal of Surgical Oncology" Springer Journals

The Big Billion Indian COVID 19 Vaccine Challenge

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/the-big-billion-indian-covid-19-vaccine-challenge-WxXHi0TwuL

References (7)

Publisher
Springer Journals
Copyright
Copyright © Indian Association of Surgical Oncology 2021
ISSN
0975-7651
eISSN
0976-6952
DOI
10.1007/s13193-021-01280-1
Publisher site
See Article on Publisher Site

Abstract

Indian Journal of Surgical Oncology (March 2021) 12(1):3–4 https://doi.org/10.1007/s13193-021-01280-1 EDITORIAL 1 2,3 Arvind Krishnamurthy & K. S. Gopinath Published online: 1 February 2021 Indian Association of Surgical Oncology 2021 The front runner vaccine candidates for India’s COVID-19 response seems to be the vaccines developed by Oxford- “My advice to anyone offered the vaccine is to take it. AstraZeneca and the Bharath Biotech thus far. Although If I can have it at 90, then you can have it too.” Pfizer India has formally approached the Drugs Controller Margaret Keenan (First person in the world to have General of India (DCGI) for EUA of its Covid-19 vaccine, th the Covid–19 vaccine on December 8 2020) there seems to be no clear roadmap for the availability of the mRNA vaccines developed by Pfizer as well as the Moderna Come 2021, COVID-19 vaccination is expected to be one in India till date. It must be noted that the specialized cold of the most eagerly awaited events in the timelines of every storage requirements for the above mRNA vaccines may be nation world-wide and India is no exception to this mammoth a deterrent to its large-scale use in India. This is a rapidly global

Journal

"Indian Journal of Surgical Oncology" – Springer Journals

Published: Feb 1, 2021

There are no references for this article.